United States· US:55154-0411_9c209f5c-9a8e-40bf-abed-1b36b368c271

Jardiance

A empagliflozin product containing empagliflozin, registered in United States by Cardinal Health 107, LLC. The same ATC class is registered in 16 of our 19 countries.

ATC A10BK03US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedJardianceATCA10BK03REGISTER NO.US:55154-0411_9c209f5…PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Empagliflozin is registered in 16 of 19 countries.

Countries holding a registration under ATC A10BK03 (empagliflozin), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 9 of them publish a price we can compare per daily dose

Empagliflozin · ATC A10BK03

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of empagliflozin costs, country by country.

Normalised to the WHO defined daily dose (17.5 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Empagliflozin · price per daily dose (17.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$3.80
  • IT Italy$2.95
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
EMPAGLIFLOZIN
Manufacturer
Cardinal Health 107, LLC
Country
United States (US)
ATC code
A10BK03
ATC class
Empagliflozin
Defined daily dose
17.5 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    5515404118
    720 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55154-0411-8)
  • ndc11
    55154-0411-8

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

466 interactions on record for empagliflozin.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Empagliflozin · interactions on record

466 records

  • 1 severe
  • 425 moderate
  • 40 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • PapaverineA03AD01moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Empagliflozin in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All empagliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Empagliflozin Denk, Empagliflozin Devatis
  • Belgium · Empagliflozin Ab, Empagliflozine Hcs
  • Bulgaria · Глузод, Емлигекса
  • Cyprus · Glusod
  • Czechia · Empagliflozin Polpharma, Empelic
  • Germany · Empagliflozin Devatis, Emprables
  • Denmark · Bifoglan, Elemio
  • Estonia · Glusod
  • Spain · Empagliflozina Aurovitas, Empagliflozina Kern Pharma
  • Finland · Empagliflozin Devatis, Empagliflozin Reddy
  • United Kingdom (Northern Ireland) · Empagliflozin, Empagliflozin G.L. Pharma
  • Greece · Elemio, Empagliflozin Pharmapath
  • Croatia · Glusod
  • Hungary · Empagliflozin Polpharma
  • Ireland · Empagliflozin Krka
  • Iceland · Empagliflozin Reddy, Empagliflozin Wh 10 Mg
  • Liechtenstein · Jardiance
  • Lithuania · Embeflyx, Emlygexa
  • Luxembourg · Empagliflozin Ab
  • Latvia · Embeflyx, Emlygexa
  • Malta · Empagliflozin Denk, Eprekavor
  • Netherlands · Empagliflozine Devatis, Empagliflozine Doc
  • Norway · Empagliflozin Devatis, Empagliflozin Reddy
  • Poland · Empelic
  • Portugal · Empagliflozina Aurobindo, Empagliflozina Aurovitas
  • Romania · Glusod
  • Sweden · Empagliflozin Devatis, Empagliflozin Labiana
  • Slovenia · Empagliflozin Krka, Glusod
  • Slovakia · Empagliflozin Polpharma, Glusod

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/06cdebf1-a15b-4215-8204-45a0044cef8c
GET /v1/drugs/06cdebf1-a15b-4215-8204-45a0044cef8c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "10",
  "substance": "EMPAGLIFLOZIN",
  "productndc": "55154-0411",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA204629",
  "marketing_category": "NDA"
}

See everything about empagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.